The estimated Net Worth of Parters Vii L P Domain is at least 55.1 百万$ dollars as of 1 July 2013. Parters Domain owns over 280,923 units of Zogenix Inc stock worth over 55,145,826$ and over the last 14 years Parters sold ZGNX stock worth over 0$.
Parters has made over 4 trades of the Zogenix Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Parters bought 280,923 units of ZGNX stock worth 3,932,922$ on 1 July 2013.
The largest trade Parters's ever made was buying 3,441,304 units of Zogenix Inc stock on 16 September 2011 worth over 6,882,608$. On average, Parters trades about 1,158,146 units every 157 days since 2010. As of 1 July 2013 Parters still owns at least 2,066,935 units of Zogenix Inc stock.
You can see the complete history of Parters Domain stock trades at the bottom of the page.
Parters's mailing address filed with the SEC is C/O DOMAIN ASSOCIATES, LLC, ONE PALMER SQUARE, PRINCETON, NJ, 08542.
Over the last 14 years, insiders at Zogenix Inc have traded over 5,100,850$ worth of Zogenix Inc stock and bought 57,764,538 units worth 193,451,745$ . The most active insiders traders include Advisors Llcperceptive Life...、Nicole Vitullo、Jesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of 13,059,406$. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth 15,000$.
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Zogenix Inc executives and other stock owners filed with the SEC include: